Skip to main content

Find Clinical Trials

Home
Conditions
Lymphoma, Follicular

Clinical trial condition

Lymphoma, Follicular

Explore clinical trials studying Lymphoma, Follicular. Study availability and eligibility vary by location and protocol.

1,362 public trials 202 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, Follicular trial results

Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT00406809

Conditions: Chronic Lymphoid Leukemia, Follicular Lymphoma, Hematologic Diseases, +25 more
Locations: Site Reference ID/Investigator# 4997 Los Angeles, California, United States

Site Reference ID/Investigator# 9104 Los Angeles, California, United States

Site Reference ID/Investigator# 2613 Bethesda, Maryland, United States

Site Reference ID/Investigator# 40243 Boston, Massachusetts, United States

View Trial Details

Completed

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

NCT02650999

Conditions: CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Hemic and Lymphatic Diseases, +11 more
Locations: Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States

View Trial Details

Completed

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

NCT03351140

Conditions: Blood Protein Disorders, Breast Diseases, Breast Neoplasms, +37 more
Locations: GSK Investigational Site Mountlake Terrace, Washington, United States

View Trial Details

Completed

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

NCT03993288

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Sandoz Investigative Site Krasnogorsk, Russia

Sandoz Investigative Site Moscow, Russia

Sandoz Investigative Site Saint Petersburg, Russia

Sandoz Investigative Site Saint Petersburg, Russia

View all 18 locations

View Trial Details

Completed

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT00726700

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations: Not specified

View Trial Details

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

NCT00794638

Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +14 more
Locations: Nagoya, Aichi-ken, Japan

Isehara, Kanagawa, Japan

Kyoto, Japan

Chuo-ku, Tokyo, Japan

View Trial Details

Completed

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

NCT00562978

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: Not specified

View Trial Details

Completed

Dignity Therapy for Patients With Early Dementia and Their Family

NCT03692988

Conditions: Brain Diseases, Central Nervous System Diseases, Dementia, +16 more
Locations: University of Zurixh Zurich, Switzerland

View Trial Details

Completed

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

NCT02093663

Conditions: Colitis, Colitis, Ulcerative, Colonic Diseases, +16 more
Locations: University of Maryland Children's Hospital Baltimore, Maryland, United States

John Hopkins Baltimore, Maryland, United States

Massachusetts General Hospital Boston, Massachusetts, United States

Newton Wellesley Hospital Newton, Massachusetts, United States

View all 33 locations

View Trial Details

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02596971

Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Rocky Mountain Cancer Center - Aurora Aurora, Colorado, United States

Georgetown University Medical Center Washington D.C., District of Columbia, United States

University Miami Miami, Florida, United States

New York Uni Medical Center New York, United States

View all 21 locations

View Trial Details